Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00049561.xml
Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(04): 261
DOI: 10.1055/s-0040-1721178
DOI: 10.1055/s-0040-1721178
Letter to the Editor
Gemcitabine in Recurrent Meningioma
Authors
FundingNone.
Publication History
Article published online:
15 June 2021
© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Euskirchen P, Peyre M. Management of meningioma. Presse Med 2018; 47 (11-12 Pt 2) e245-e252
- 2 Kaley T, Barani I, Chamberlain M. et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncol 2014; 16 (06) 829-840
- 3 Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 2009; 92 (01) 1-6
- 4 Takeda H, Okada M, Kuramoto K. et al. Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo. Oncotarget 2017; 8 (53) 90996-91008